{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:18Z","timestamp":1794047478482,"version":"4.8.0"},"reference-count":24,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"12","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The value of quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify the M-protein is being investigated in patients with monoclonal gammopathies but no data are yet available in high-risk smoldering myeloma (HRsMM). We have, therefore, investigated QIP-MS to monitor peripheral residual disease (PRD) in 62 HRsMM patients enrolled in the GEM-CESAR trial. After 24 cycles of maintenance, detecting the M-protein by MS or clonal plasma cells by next-generation flow cytometry (NGF) identified cases with a significantly shorter median progression-free survival (mPFS) (MS: not reached vs. 1.4 years, P=0.001; NGF: not reached vs. 2 years, P=0.0002) but reaching complete response (CR) + stringent CR (sCR) did not discriminate between patients with different outcome. With NGF as a reference, the combined results of NGF and MS showed a high negative predictive value (NPV) of MS: 81% overall and 73% at treatment completion. When sequential results were considered, sustained negativity by MS or NGF was associated with a very favorable outcome with an mPFS not yet reached versus 1.66 years and 2.18 years in cases never attaining PRD or minimal residual disease (MRD) negativity, respectively. We can, thus, conclude that: 1) the standard response categories of the International Myeloma Working Group do not seem to be useful for monitoring treatment in HRsMM patients; 2) MS could be used as a valuable, non-invasive, clinical tool with the capacity of guiding timely bone marrow evaluations (based on its high NPV with NGF as a reference); and 3) similarly to NGF, sequential results of MS are able to identify a subgroup of HRsMM patients with long-term disease control. This study was registered at www.clinicaltrials.gov (clinicaltrials.gov identifier: 02415413).<\/jats:p>","DOI":"10.3324\/haematol.2024.285742","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T03:40:01Z","timestamp":1720669201000},"page":"4056-4066","source":"Crossref","is-referenced-by-count":8,"title":["Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial"],"prefix":"10.3324","volume":"109","author":[{"given":"Noem\u00ed","family":"Puig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Agull\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Juan","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Aires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Jos\u00e9","family":"Calasanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Garc\u00eda-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodr\u00edguez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Gonz\u00e1lez-Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta S","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma C","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"R\u00edos-Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-\u00c1ngel","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Bargay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Pilar","family":"Gonz\u00e1lez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Alegre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Escalante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Bel\u00e9n","family":"I\u00f1igo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"De la Rubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Isabel","family":"Teruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"De Arriba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Palomera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel T","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"L\u00f3pez-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Reinoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ar\u00e1nzazu","family":"Garc\u00eda-Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique M","family":"Ocio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Jos\u00e9","family":"Lahuerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Teresa","family":"Cedena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas F San","family":"Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"70117","doi-asserted-by":"crossref","unstructured":"Lahuerta JJ, Paiva B, Vidriales MB. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials. J Clin Oncol. 2017; 35(25):2900-2910.","DOI":"10.1200\/JCO.2016.69.2517"},{"key":"70118","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-346."},{"key":"70119","doi-asserted-by":"crossref","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020; 4(23):5988-5999.","DOI":"10.1182\/bloodadvances.2020002827"},{"key":"70120","doi-asserted-by":"crossref","unstructured":"Sanoja-Flores L, Flores-Montero J, Puig N. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood. 2019; 134(24):2218-2222.","DOI":"10.1182\/blood.2019002610"},{"key":"70121","doi-asserted-by":"crossref","unstructured":"Mazzotti C, Buisson L, Maheo S. Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv. 2018; 13(2):2811-2813.","DOI":"10.1182\/bloodadvances.2018025197"},{"key":"70122","doi-asserted-by":"crossref","unstructured":"Zajec M, Langerhorst P, VanDuijn MM. Mass spectrometry for identification, monitoring, and minimal residual disease detection of M-proteins. Clin Chem. 2020; 66(3):421-433.","DOI":"10.1093\/clinchem\/hvz041"},{"key":"70123","doi-asserted-by":"crossref","unstructured":"Puig N, Contreras MT, Agull\u00f3 C. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Adv. 2022; 6(11):3234-3239.","DOI":"10.1182\/bloodadvances.2021006762"},{"key":"70124","doi-asserted-by":"crossref","unstructured":"Fan H, Wang B, Shi L. Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum M-protein using mass spectrometry (EasyM). Clin Cancer Res. 2024; 30(6):1131-1142.","DOI":"10.1158\/1078-0432.CCR-23-2767"},{"key":"70125","doi-asserted-by":"crossref","unstructured":"Martins CO, Huet S, Yi SS. Mass spectrometry-based method targeting Ig variable regions for assessment of minimal residual disease in multiple myeloma. J Mol Diagnostics. 2020; 22(7):901-911.","DOI":"10.1016\/j.jmoldx.2020.04.002"},{"key":"70126","doi-asserted-by":"crossref","unstructured":"Kyle RA, Durie BG, Rajkumar SV. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010; 24(6):1121-1127.","DOI":"10.1038\/leu.2010.60"},{"key":"70127","doi-asserted-by":"crossref","unstructured":"Kyle RA, Remstein ED, Therneau TM. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007; 356(25):2582-2590.","DOI":"10.1056\/NEJMoa070389"},{"key":"70128","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Persona E, Vidriales MB, Mateo G. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007; 110(7):2586-2592.","DOI":"10.1182\/blood-2007-05-088443"},{"key":"70129","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-548.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"70130","doi-asserted-by":"crossref","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017; 31(10):2094-2103.","DOI":"10.1038\/leu.2017.29"},{"key":"70131","doi-asserted-by":"crossref","unstructured":"Santockyte R, Jin C, Pratt J. Sensitive multiple myeloma disease monitoring by mass spectrometry. Blood Cancer J. 2021; 11(4):78.","DOI":"10.1038\/s41408-021-00473-9"},{"key":"70132","doi-asserted-by":"crossref","unstructured":"Dispenzieri A, Krishnan A, Arendt B. Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMTCTN0702\/07LT). Blood Cancer J. 2022; 12(2):27.","DOI":"10.1038\/s41408-022-00624-6"},{"key":"70133","doi-asserted-by":"crossref","unstructured":"Campbell L, Simpson D, Ramasamy K SR. Using quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify low level monoclonal proteins. Clin Biochem. 2021; 95:81-83.","DOI":"10.1016\/j.clinbiochem.2021.05.012"},{"key":"70134","doi-asserted-by":"crossref","unstructured":"Mai EK, Huhn S, Miah K. Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma. Blood Cancer J. 2023; 13(1):1-10.","DOI":"10.1038\/s41408-022-00772-9"},{"key":"70135","doi-asserted-by":"crossref","unstructured":"Durie BGM, Harousseau JL, Miguel JS. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20(9):1467-1473.","DOI":"10.1038\/sj.leu.2404284"},{"key":"70136","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-L\u00f3pez J, Paiva B, L\u00f3pez-Anglada L. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood. 2015; 126(7):858-862.","DOI":"10.1182\/blood-2015-04-638742"},{"key":"70137","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Ubieto A, Paiva B, Puig N. Validation of the International Myeloma Working Group standard response criteria in the PETHEMA\/GEM2012MENOS65 study: are these times of change?. Blood. 2021; 138(19):1901-1905.","DOI":"10.1182\/blood.2021012319"},{"key":"70138","doi-asserted-by":"crossref","unstructured":"San-Miguel J, Avet-Loiseau H, Paiva B. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022; 139(4):492-501.","DOI":"10.1182\/blood.2020010439"},{"key":"70139","doi-asserted-by":"crossref","unstructured":"Paiva B, Manrique I, Dimopoulos MA. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials. Blood. 2023; 141(6):579-591.","DOI":"10.1182\/blood.2022016782"},{"key":"70140","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H, San-Miguel J, Casneuf T. Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR. J Clin Oncol. 2021; 39(10):1139-1149.","DOI":"10.1200\/JCO.20.01814"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285742\/77257","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285742\/77840","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11683\/77257","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:53Z","timestamp":1794046013000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285742","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,11]]}}}